摘要
程序性死亡受体1/程序性死亡受体1配体（PD-1/PD-L1）靶点阻断剂已被美国食品药品监督管理局（FDA）批准用于治疗黑色素瘤、非小细胞肺癌、肾癌等实体肿瘤,随后对胃肠道实体肿瘤治疗也开展了初步研究,并取得了一定疗效,显示了较好的应用前景,但同时也发现一些局限性.文章对免疫治疗在胃癌治疗中的研究进展进行综述.
Immunotherapy targeted on programmed death 1 （PD-1） and programmed death 1 ligand （PD-L1） has been approved by US Food and Drug Administration （FDA） for the treatment of solid tumors such as melanoma, non-small cell lung cancer and renal cell carcinoma. Preliminary study on the gastrointestinal solid tumor has been carried out, which has shown favorable efficacies and promising application prospect. However, some disadvantages have appeared. This article reviews the progress of immunotherapy for gastric adenocarcinoma.
出处
《肿瘤研究与临床》
CAS
2018年第1期69-72,共4页
Cancer Research and Clinic
基金
山西省科技攻关计划（20150313007-7）
